Annual report pursuant to Section 13 and 15(d)

Note 2 - Acquisitions (Details Textual)

Note 2 - Acquisitions (Details Textual) $ in Thousands									3 Months Ended		5 Months Ended	6 Months Ended	10 Months Ended	12 Months Ended
Note 2 - Acquisitions (Details Textual) $ in Thousands	Jun. 30, 2018 USD ($)	Feb. 01, 2018 USD ($)	Jan. 02, 2018 USD ($)	Sep. 05, 2017 USD ($)	Aug. 01, 2016 USD ($)	Jul. 01, 2016 USD ($)	Mar. 14, 2016 USD ($)	Jul. 08, 2015 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2017 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)
Payments to Acquire Businesses, Net of Cash Acquired, Total														$ 67,851	$ 253,785	$ 91,423
Goodwill, Purchase Accounting Adjustments															1,809
Business Combination, Contingent Consideration, Liability, Total															68,400
Payment for Contingent Consideration Liability, Financing Activities														61,900	$ 20,316
Trevigen Inc. [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total	10,644			$ 10,634
Business Acquisition, Goodwill, Expected Tax Deductible Amount				$ 0
Goodwill, Purchase Accounting Adjustments													1,396
Trevigen Inc. [Member] \| Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life				13 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	5,100			$ 3,800					5,100		5,100	5,100	5,100	5,100
Trevigen Inc. [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life				11 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	260			$ 1,900					260		260	260	260	260
Trevigen Inc. [Member] \| Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life				1 year 182 days
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	160			$ 1,400					160		160	160	160	160
Atlanta Biologicals [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total	51,274		$ 51,286
Business Acquisition, Goodwill, Expected Tax Deductible Amount			0
Goodwill, Purchase Accounting Adjustments												(11,500)
Business Combination, Consideration Transferred, Total			$ 51,300
Atlanta Biologicals [Member] \| Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life			13 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	23,000		$ 9,000						23,000		23,000	23,000	23,000	23,000
Atlanta Biologicals [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life			12 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	3,600		$ 1,500						3,600		3,600	3,600	3,600	3,600
Atlanta Biologicals [Member] \| Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life			15 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	2,300		$ 1,000						2,300		2,300	2,300	2,300	2,300
Eurocell Diagnostics, SAS [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total	5,933	$ 3,136
Business Acquisition, Goodwill, Expected Tax Deductible Amount		0
Goodwill, Purchase Accounting Adjustments											2,797
Business Combination, Consideration Transferred, Total		7,300
Payments to Acquire Businesses, Gross		6,000
Business Combination, Consideration Transferred, Liabilities Incurred	1,396	$ 1,396
Eurocell Diagnostics, SAS [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life		7 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	6,272	$ 6,272							6,272		6,272	6,272	6,272	6,272
Advanced Cell Diagnostics (ACD) [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total					$ 247,000									247,038
Business Combination, Consideration Transferred, Total														287,638
Payments to Acquire Businesses, Gross					258,000
Business Combination, Consideration Transferred, Liabilities Incurred					11,000									3,600
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	75,000				$ 75,000				75,000		75,000	75,000	75,000	75,000
Business Combination, Consideration Transferred, Employee Vesting Period					1 year 180 days
Advanced Cell Diagnostics (ACD) [Member] \| Pre-acquisition Services [Member]
Business Combination, Consideration Transferred, Liabilities Incurred					$ 3,600
Advanced Cell Diagnostics (ACD) [Member] \| Future Services [Member]
Business Combination, Consideration Transferred, Liabilities Incurred					7,400
Advanced Cell Diagnostics (ACD) [Member] \| The 2016 Revenue Equal or Exceed $30 Milliom [Member]
Business Combination, Contingent Consideration, Liability, Total					25,000
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue					30,000
Advanced Cell Diagnostics (ACD) [Member] \| The 2017 Revenues Equal or Exceed $45 Million [Member]
Business Combination, Contingent Consideration, Liability, Total					50,000
Business Combination, Contingent Consideration, Liability, Trigger Amount of Revenue					$ 45,000
Space [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total						$ 6,700								6,747
Business Combination, Consideration Transferred, Total														9,003
Payments to Acquire Businesses, Gross						9,000
Business Combination, Consideration Transferred, Liabilities Incurred						$ 2,300								2,256
Zephyrus [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total														8,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount							$ 0
Business Combination, Consideration Transferred, Total														14,500
Payments to Acquire Businesses, Gross							8,000
Business Combination, Consideration Transferred, Liabilities Incurred
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 7,000						7,000		7,000		$ 7,000	$ 7,000	$ 7,000	7,000
Payment for Contingent Consideration Liability, Financing Activities									$ 3,500	$ 3,500
Zephyrus [Member] \| Instruments Sales Contingency [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High							$ 3,500
Business Combination, Contingent Consideration, Liability, Number of Instruments Sold							10
Business Combination, Contingent Consideration, Liability, Anniversary of Closing Date							3 years
Business Combination, Contingent Consideration, Liability, Cumulative Sales							$ 3,000
Business Combination, Contingent Consideration, Liability, Number of Years Within Closing Date							4 years 182 days
Zephyrus [Member] \| Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							$ 7,400
Cliniqa [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total								$ 82,900						82,888
Business Combination, Consideration Transferred, Total														82,888
Business Combination, Consideration Transferred, Liabilities Incurred